Myeloma Trial, Recruiting NCT06783816 Sponsor: Shanxi Bethune Hospital Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06783816
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your legal guardian) are willing to sign a consent form and are able to attend all planned visits and follow study procedures
  • Your blood cancer has been confirmed by laboratory testing to have certain markers on the cancer cells (called CD19, CD22, and/or BCMA)
  • You are between 15 and 80 years old
  • You meet at least one of these conditions: your cancer came back or did not respond after trying one standard treatment and one additional treatment; small amounts of cancer remain after those two treatments; or your cancer came back after a stem cell transplant
  • Your doctors expect you to live for at least 12 weeks
  • Your kidneys, liver, and heart are working reasonably well, based on specific blood test results and a heart scan
  • Your overall physical ability to carry out daily activities falls within an acceptable range (rated 0–3 on a standard scale used by doctors)
  • If you are a child, your guardian is able to sign the consent form on your behalf

Who may not be able to join:

  • You have had serious heart problems in the past year, such as a heart attack, stenting, unstable chest pain, or severe heart failure, or a specific abnormal heart rhythm reading was found during screening
  • You currently have graft-versus-host disease (a complication sometimes seen after transplants) or need medicines that suppress your immune system
  • You have had another type of cancer within the last 5 years (with some exceptions for certain fully treated skin or early-stage cancers — confirm with trial site)
  • You have had an active or uncontrolled infection needing treatment in the 7 days before screening (minor urinary or common cold-type infections may be exceptions — confirm with trial site)
  • You have active Hepatitis B, Hepatitis C, HIV, a certain type of herpes virus (CMV), or syphilis detected in your blood
  • You took part in another clinical trial within the past 4 weeks, or the last trial drug has not fully cleared your system yet
  • You have had a severe allergic reaction to a biological medicine in the past
  • You have serious unstable conditions affecting your liver, kidneys, or metabolism that require ongoing medical treatment
  • You are pregnant, breastfeeding, or planning to become pregnant within 2 years after receiving the treatment; or you are male and your partner plans to become pregnant within 2 years after your treatment
  • The trial doctors believe your condition could put you at higher risk or affect the trial results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: CHN13986102084

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanxi Bethune Hospital
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
1 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

monitor the survival time of CAR-T in vivo; Record antitumor effects after reinfusion of CAR-T

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov